Showing 5401-5410 of 5621 results for "".
- Recipients of the 2018 OWL Awards Recognized for Advancing Diversity in Ophthalmology Leadershiphttps://modernod.com/news/recipients-of-the-2018-owl-awards-recognized-for-advancing-diversity-in-ophthalmology-leadership/2479662/OWL: Advancing Diversity in Leadership (OWL) announced the winners of the 2018 OWL Awards at the organization’s Signature Event, which was held October 28 in Chicago during the annual meeting of the American Academy of Ophthalmology (AAO 2018). OWL presents the awards each year to those who best
- Eyepatch With Dissolvable Needles Used to Treat Eye Diseasehttps://modernod.com/news/eyepatch-with-dissolvable-needles-used-to-treat-eye-disease/2479667/A team of researchers affiliated with several institutions in Singapore has developed an eyepatch with dissolvable needles for use in treating eye diseases, according to a report in Medical Xpress.
- Eyegate Pharma Announces Positive Results in Second PRK Studyhttps://modernod.com/news/eyegate-pharma-announces-positive-results-in-second-prk-study/2479671/EyeGate Pharmaceuticals announced topline data from its study evaluating the potential of EyeGate’s Ocular Bandage Gel (OBG) to help clinicians better manage corneal epithelial defects in patients following photorefractive keratectomy (PRK) surgery, compared to current standard of care. “T
- Ophthotech Announces Results from Phase 2a Safety Trial of Zimura in Combination with Lucentis in Wet AMDhttps://modernod.com/news/ophthotech-announces-results-from-phase-2a-safety-trial-of-zimura-in-combination-with-lucentis-in-wet-amd/2479673/Ophthotech announced the results from its phase 2a safety trial of Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combinat
- Small-Particle Air Pollution May Raise Glaucoma Risk in Somehttps://modernod.com/news/small-particle-air-pollution-may-raise-glaucoma-risk-in-some/2479675/In people who already have a genetic vulnerability, small-particle air pollution known as black carbon may raise the risk of developing glaucoma, a new study suggests, according to a Reuters report. Researchers found that in older
- AsclepiX Therapeutics Raises $5 Million to Advance Therapies in AMD and DMEhttps://modernod.com/news/asclepix-therapeutics-raises-5-million-to-advance-therapies-in-amd-and-dme/2479676/AsclepiX Therapeutics announced that it has raised $5 million in convertible note funding to accelerate development of AXT107, its treatment for two leading causes of adult blindness: diabetic macular edema (DME) and wet age-related macular degeneration (AMD). These diseases are now treated with
- Calcified Nodules Linked to AMD Progressionhttps://modernod.com/news/calcified-nodules-linked-to-amd-progression/2479682/The presence of a specific type of calcified nodule in the retinal drusen of patients with age-related macular degeneration (AMD) is associated with a more than sixfold increased risk for late-stage progression of the disease, a study has shown, according to a Medscape
- Prevent Blindness Elects Three New Members to National Board of Directorshttps://modernod.com/news/prevent-blindness-elects-three-new-members-to-national-board-of-directors-2/2479700/Prevent Blindness has announced that Paul Delatore, Global Head, Market Access at Alcon; Jim McGrann, Chairman & CEO of Healthy Eyes Advantage; and Rajeev S. Ramchandran, MD, Associate Professor of Ophthalmology in the University of Rochester Medical School’s Department of Ophthalmology, have
- SemaThera Board Names Garth Cumberlidge as President & CEOhttps://modernod.com/news/semathera-board-names-garth-cumberlidge-as-president-ceo/2479705/SemaThera announced that its board of directors has appointed Garth Cumberlidge as President and Chief Executive Officer. Dr. Cumberlidge was also elected to the board of directors of SemaThera. He will lead the company’s development programs in diabetic macular edema and other degenerative retin
- Johnson & Johnson Vision to Showcase New Data and Interactive Experiences at 2018 AAOpthttps://modernod.com/news/johnson-johnson-vision-to-showcase-new-data-and-interactive-experiences-at-2018-aaopt/2479707/Johnson & Johnson Vision will highlight new data at the 2018 American Academy of Optometry Annual Meeting (Academy 2018), held November 7-10 in San Antonio, Texas. Two paper presentations highlighting visual performance of photochromic contact lenses were designated among the “Most Newsworthy